From Research to Rising Stocks: What Sets the Psilocybin Industry Apart
Much like the cannabis industry, recent legalization for psychedelics in cities and states across the U.S. has fueled a resurgence in psychedelics. However, this resurgence is also due to a renewed interest in research into psychedelics in Canada. Both factors have led to the rise in stocks for psychedelics companies in the industry that are working with psilocybin.
Psilocybin is the active compound in psilocybin mushrooms, known more popularly as magic mushrooms. Psilocybin is the element that triggers the psychedelic effect in a consumer’s brain. However, psilocybin is not just found in mushrooms. It can also be synthesized in a number of different ways in a lab setting.
In numerous studies, psilocybin has proven to be effective in treating several mental health disorders and conditions. The use of psilocybin can help with conditions like anxiety, opioid withdrawal, seasonal affective disorder (SAD), and attention deficit hyperactivity disorder (ADHD). While there are different drugs on the market that can also help with these conditions, not all of them are effective for all people. Current research into psilocybin suggests that it might be more effective than alternative treatments for people who suffer from these conditions.
How companies in the industry use psilocybin therapy
One of the many ways that psychedelics companies are utilizing psilocybin is through psilocybin therapy. This approach is currently being studied. It combines the effects of psilocybin with mental health counseling to further optimize the effects of each.
Early studies into psilocybin therapy suggest that it may be a safe and effective way to treat depression, anxiety, addiction, and other mental illnesses. This is especially true when psilocybin is administered and supported by specially-trained therapists.
Psilocybin therapy begins with a patient and therapist getting to know one another. Once they feel comfortable with each other, the patient receives their dose of psilocybin in a comfortable room. The therapist remains with them throughout their session, which can last from 6-8 hours. During those hours, the patient is encouraged to generate their own insights on their emotional and behavioral patterns. The dose of psilocybin helps patients to move more easily into a state of mental and emotional clarity.
Why is the industry interested in psilocybin?
If the current trends hold, psilocybin could turn out to be a game changer. It has the potential to help millions of people who are currently living with a wide range of mental health conditions. If it is fully legalized and recognized by federal health organizations, psilocybin has the potential to be the next big pharmaceutical hit.
For more information and to stay up-to-date on psychedelics stocks and the industry as a whole, be sure to check back in with The Dales Report.